Quantumzyme is an early-stage biotech company that engineers enzymes as cleaner alternatives to traditional chemical catalysts used in industrial manufacturing, primarily pharmaceutical API production. The core concept is biocatalysis — replacing conventional chemical reactions, which often require hazardous reagents and generate significant waste, with engineered enzymes that achieve the same transformations under milder, greener conditions. Quantumzyme's only developed product is an engineered enzyme designed to replace the carcinogenic catalyst used in Ibuprofen API manufacturing. The company's intended business model is technology licensing: Quantumzyme engineers and validates an enzyme, then licenses the technology to API manufacturers or pharma companies, collecting upfront technology transfer fees and ongoing royalties tied to production volumes. Third-party manufacturers would handle scale-up, production, and regulatory compliance, keeping Quantumzyme asset-light. Beyond Ibuprofen, Quantumzyme has stated ambitions to expand into additional pharmaceutical APIs and eventually adjacent markets including fragrances, flavors, and carbon capture. In practice, Quantumzyme is pre-revenue, has one employee, has no patents filed on its core product, and has not yet signed any licensing agreements. The company uses quantum mechanics and molecular modeling to design enzymes, which it argues enables more precise and cost-competitive solutions compared to larger incumbents.